Tech and Science Daily | The Standard

Al’s back with your London-first tech and science sprint. Sutton just waved through a £1bn expansion of the London Cancer Hub — yes, it’s labs, but also somehow a pub and padel court. Then we hit the UK’s Data (Use and Access) Act updates landing today, before a quick detour into a promising new CAR-T-style cancer treatment result (mouse-mode, but still exciting). After the break: NASA’s Artemis II timing, Nintendo’s Partner Showcase, and Google teasing the Pixel 10a with UK pre-orders locked for 18 Feb. More at standard.co.uk — and follow for your weekday briefing. Hosted on Acast. See acast.com/privacy for more information.

Today: a Lancet study puts an AI stethoscope through its paces in 205 London GP surgeries — aiming to catch serious heart conditions earlier. The government’s dropped a brand-new National Cancer Plan for England, with big survival targets and big promises. Plus, the International AI Safety Report 2026 lands with fresh warnings about deepfakes and rising risk… before we lighten it up with a next-gen Xbox timeline tease and a look at the Fairphone 6, built for people who’d rather repair than replace. More at standard.co.uk. Hosted on Acast. See acast.com/privacy for more information.

For this episode of Brave New World, Evgeny is joined by psychologist, author, and researcher Dr Jim Fadiman, a central figure in the modern understanding of psychedelics, who also goes by the “father of microdosing”.
Drawing on decades of research and thousands of user reports, the conversation traces the history of psychedelics - from early scientific study in the 1950s and 60s, through prohibition, to today’s renewed interest in clinical and psychiatric settings. Jim discusses why most formal research has focused on high doses, how observational reports have shaped microdosing research, where evidence is strongest and still emerging.
Evgeny and Jim look ahead to the future of psychedelics in medicine, the balance between scientific caution and public interest, and what a first step might look like for someone curious but sceptical.

Hosted on Acast. See acast.com/privacy for more information.

Alan Leers is on with your weekday tech-and-science fix from London. Today: a new Imperial-led study asks if Boots and Tesco loyalty card data — from consenting volunteers — could help spot early cancer warning signs sooner. Plus, why handwriting is making a comeback (yes, really), Valheim celebrates five years of Viking chaos, and Notepad++ issues a sobering reminder that software updates need proper security behind them. For more, hit standard.co.uk — and follow Tech and Science Daily so you’re never the last to know.

Hosted on Acast. See acast.com/privacy for more information.

Alan Leer is on mic in London, and today’s briefing is basically: cleaner transport, messier politics, and the internet doing internet things. West Ealing to Greenford becomes the unlikely star of the show as a battery-only train starts carrying passengers. Then it’s a UK science funding wobble, before we head online: Google says it’s smashed a massive proxy network, and an antivirus update story proves reality still writes the worst plot twists. In gaming, Apex Legends gives the original Switch an expiry date, and Apple quietly keeps older iPhones on life support — because not everyone’s upgrading every year, are they? More at standard.co.uk. Hosted on Acast. See acast.com/privacy for more information.